Showing 3621-3630 of 7238 results for "".
- Analysis: Global Prevalence of Hidradenitis Suppurativa Higher Than Previously Estimatedhttps://practicaldermatology.com/news/analysis-global-prevalence-of-hidradenitis-suppurativa-higher-than-previously-estimated/2483148/The estimate of the global prevalence of hidradenitis suppurativa (HS) sits at 0.99%, which notably higher than prior global figures, according to a new analysis. The research team compiled data from 25 population-based studies
- Review: Psoriasis May Increase Infection Risk After Hip Arthroplastyhttps://practicaldermatology.com/news/review-psoriasis-may-increase-infection-risk-after-hip-arthroplasty/2483053/Patients with psoriasis undergoing total hip arthroplasty (THA) may face a higher risk of postoperative infection, with evidence regarding total knee arthroplasty (TKA) outcomes remaining inconclusive, according to a new systematic review,
- HS Patients on Adalimumab Face Higher Risk of Serious Infections than PsO Counterpartshttps://practicaldermatology.com/news/hs-patients-on-adalimumab-face-higher-risk-of-serious-infections-than-pso-counterparts/2483028/Patients with hidradenitis suppurativa (HS) initiating adalimumab face a significantly higher risk of serious, noncutaneous infections requiring hospitalization compared with patients with psoriasis, a new cohort study finds.
- Dual-Wavelength Laser Caps Gain Clinical Validation for Hair Density Gainshttps://practicaldermatology.com/news/dual-wavelength-laser-caps-gain-clinical-validation-for-hair-density-gains/2476121/KeraFactor announced that it will be spotlighting its dermatologist-developed hair health solutions this August in recognition of National Hair Loss Awareness Month, according to a news release from the manufacturer. The bran
- New: Researchers ID Polygenic Signature in Sporadic HShttps://practicaldermatology.com/news/researchers-identify-polygenic-signature-in-sporadic-hs/2476099/Researchers on a new study proposed a polygenic score (PGS) model that points to a genetic contribution to susceptibility in sporadic hidradenitis suppurativa (spHS). Publishing in the Journal of Investigative Dermatology
- FDA Speeds Development of Hair Loss Drug Rezpegaldesleukinhttps://practicaldermatology.com/news/fda-speeds-development-of-nektars-autoimmune-hair-loss-drug/2475953/The FDA has granted Fast Track designation to the investigational biologic rezpegaldesleukin (Nektar Therapeutics) for the treatment of severe-to-very severe alopecia areata (AA) in adults and adolescents aged 12 and older who weigh at least 40 kg.
- Data Show HS Tied to Elevated Depression, Anxiety Riskhttps://practicaldermatology.com/news/data-show-hs-tied-to-elevated-depression-anxiety-risk/2475943/Patients with hidradenitis suppurativa (HS) face elevated risk of developing new-onset depression and anxiety compared with the general population, according to findings from a population-based cohort. The analysis included 1
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- Study Shows Poor Cardiovascular–Kidney–Metabolic Health Raises Risk of PsOhttps://practicaldermatology.com/news/poor-cardiovascularkidneymetabolic-health-raises-risk-of-pso/2475773/Adults with poor cardiovascular–kidney–metabolic (CKM) health face significantly higher risks of developing psoriasis and reduced life expectancy if diagnosed, new research reveals. The analysis of data from a large UK Bioba
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of